OpGen to continue UTI panel study as planned, shares up

CapForce

05/04/2022 13:27

** Shares of diagnostic company  OPGN.O  up 6.4% at $0.83
premarket
    ** OPGN says patient enrollment at its clinical trial
testing its Unyvero urinary tract infection (UTI) panel will
continue as planned, after results from an interim analysis
 urn:newsml:reuters.com:*:nGNX4LZrq4
    ** The goal of the interim analysis was to confirm the
absence of variations in results between the different testing
sites in the study and that data collection was executed as
planned - co
    ** OPGN says the analysis of initial 150 U.S. patient
samples showed that the clinical trial protocol has been
implemented as planned 
    ** Co says it plans to continue enrollment towards its goal
of 1,500 prospective samples without any changes
    ** Co plans to include data from the study in its submission
to the U.S. FDA for approval of the panel
    ** Stock down 22% YTD, up to the last close

 (Reporting by Amruta Khandekar in Bengaluru)
 ((Amruta.Khandekar@thomsonreuters.com;))